CD8A and cancer: Eftilagimod alfa (efti), a soluble LAG-3 protein that binds to a subgroup of MHC class II molecules and mediates APC activation and CD8 T cell activation, is expected to stimulate dendritic cells and increase lymphocyte recruitment, which may lead to stronger anti-cancer responses compared to the effects of pembrolizumab alone [592].